Trial Profile

A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects With Atopic Dermatitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 27 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Roflumilast (Primary)
Indications Atopic dermatitis
Focus Adverse reactions; Registrational
Acronyms INTEGUMENT-OLE
Sponsors Arcutis Biotherapeutics

Most Recent Events

18 Mar 2026 According to an Arcutis Biotherapeutics media release, data from the trial will be presented during the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31 in Denver.
10 Mar 2026 Results presented in the Arcutis Biotherapeutics media release.
24 Oct 2025 Results presented in the Arcutis Biotherapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com